Cargando…
Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report
BACKGROUND: Complement component 3 (C3) glomerulopathy, which includes dense deposit disease (DDD) and C3 glomerulonephritis, is caused by dysregulation of the alternative complement pathway. In most cases, C3 glomerulopathy manifests pathologically with membranoproliferative glomerulonephritis-like...
Autores principales: | Hirashio, Shuma, Satoh, Ayaka, Arima, Takahiro, Mandai, Kouichi, Awaya, Tadasuke, Oshima, Kumi, Hara, Shigeo, Masaki, Takao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934801/ https://www.ncbi.nlm.nih.gov/pubmed/29724182 http://dx.doi.org/10.1186/s12882-018-0905-6 |
Ejemplares similares
-
A case of immunotactoid glomerulopathy with false-negative IgG staining
por: Hirashio, Shuma, et al.
Publicado: (2018) -
A Case of Fibronectin Glomerulopathy Caused by Missense Mutations in the Fibronectin 1 Gene
por: Hirashio, Shuma, et al.
Publicado: (2017) -
Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance
por: Lee, Holly, et al.
Publicado: (2019) -
Monoclonal gammopathy-associated pauci-immune extracapillary-proliferative glomerulonephritis successfully treated with bortezomib
por: Grundmann, Franziska, et al.
Publicado: (2013) -
Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen
por: Quattrocchio, Giacomo, et al.
Publicado: (2020)